Immune checkpoint inhibitors (ICIs) show their action by amplifying T cell-mediated immune response against cancer cells, by blocking the intrinsic down-regulators of immunity, such as programmed cell death 1 (PD-1), programmed cell death ligand 1 (PD-L1), and cytotoxic T-lymphocyte antigen 4 (CTLA-4). Here, CTLA4 is linked to cancer.